1-3 of 3
Joel McIntosh
Close
Sort by
Journal Articles

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Deyi Zhang, Hailey M. Harris, Jonathan Chen, Jen Judy, Gabriella James, Aileen Kelly, Joel McIntosh, Austin Tenn-McClellan, Eileen Ambing, Ying Siow Tan, Hao Lu, Stefan Gajewski, Matthew C. Clifton, Stephanie Yung, Daniel W. Robbins, Mehdi Pirooznia, Sigrid S. Skånland, Erika Gaglione, Maissa Mhibik, Chingiz Underbayev, Inhye E. Ahn, Clare Sun, Sarah E. M. Herman, Mark Noviski, Adrian Wiestner
Journal: Blood
Blood (2023) 141 (13): 1584–1596.
https://doi.org/10.1182/blood.2022016934
Published: 2023
Includes: Supplemental data
Journal Articles

Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies

Daniel W Robbins, Aileen Kelly, PhD, May Tan, Joel McIntosh, Jeffrey Wu, Zef Konst, Daisuke Kato, Ge Peng, Jeff Mihalic, Dahlia Weiss, Luz Perez, Jennifer Tung, Anna Kolobova, Sasha Borodovsky, PhD, Ryan Rountree, Austin Tenn-McClellan, Mark Noviski, Jordan Ye, Steve Basham, Timothy Ingallinera, Jenny McKinnell, Dane E Karr, Janine Powers, PhD, Cristiana Guiducci, PhD, Arthur Sands
Journal: Blood
Blood (2020) 136 (Supplement 1): 34.
https://doi.org/10.1182/blood-2020-141461
Published: 2020
Journal Articles

Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies

Aileen Kelly, PhD, Daniel W Robbins, May Tan, Austin Tenn-McClellan, Joel McIntosh, Jeffrey Wu, Zef Konst, Daisuke Kato, Luz Perez, Jennifer Tung, Anna Kolobova, Timothy Ingallinera, Jenny McKinnell, Dahlia Weiss, Mark Noviski, Jordan Ye, Ge Peng, Mario Cardozo, Jeff Mihalic, Steve Basham, Ryan Rountree, Dane E Karr, Neil Bence, Christoph W Zapf, Arthur T Sands
Journal: Blood
Blood (2019) 134 (Supplement_1): 3805.
https://doi.org/10.1182/blood-2019-129262
Published: 2019